An update on HAART: part 2

Home > PJ (current issue) > CPD

The Pharmaceutical Journal
Vol 276 No 7404 p693-696
10 June 2006

This article
Reprint Photocopy

PDF 80K, Acrobat Reader

Continuing professional development

An update on HAART: part 2

In part 2 of an article on antiretroviral therapy for patients with HIV, Rosy Weston, Simon Portsmouth and Andrew Benzie look at protease inhibitors and entry inhibitors, as well as further issues related to drug therapy

Continuing professional development articles

Rosy Weston, MRPharmS, RegPharmNZ, is senior principal pharmacist (HIV and sexual health), Simon Portsmouth, MRCP, MBChB, is consultant physician (HIV and sexual health) and Andrew Benzie, MRCP, MRPharmS, is specialist registrar (HIV and sexual health), all at St Mary’s NHS Trust Hospital, London

SUMMARY

Since 1996, the care of individuals living with HIV has been transformed by highly active antiretroviral therapy (HAART), where a combination of three or more antiretrovirals is used as treatment. There are now four classes of antiretrovirals. The introduction of protease inhibitors in 1996 had a dramatic effect on altering morbidity and mortality in HIV-infected individuals.

Full article PDF 80K